A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer

New England Journal of Medicine

Volumn 343, Issue 17, 2000, Pages 1217-1222

  Keller, Steven M ^a   Adak, Sudeshna ^b   Wagner, Henry ^c   Herskovic, Arnold ^d   Komaki, Ritsuko ^e   Brooks, Burke J ^f   Perry, Michael C ^g   Livingston, Robert B ^h   Johnson, David H ⁱ  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Oakwood Hospital   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f OCHSNER MEDICAL CENTER   (United States)

^g UNIVERSITY OF MISSOURI   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION FIELD; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK; SURVIVAL ANALYSIS;

EID: 0034718966     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200010263431703     Document Type: Article

References (22)

1. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma
2. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung
3. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer
4. Cisplatin dose intensity in non-small cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen
5. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer
6. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer
7. A new international staging system for lung cancer
8. Clinical staging of primary lung cancer
9. A network algorithm for performing Fisher's exact test in rxc contingency tables
10. Nonparametric estimation of incomplete observations
11. Evaluation of survival data and two new rank order statistics arising in its consideration
12. Regression models and life-tables
13. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials
14. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
15. Postoperative radiotherapy in radically resected non-small cell lung cancer
16. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: Results of a randomized prospective study
17. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma: A randomized trial of 267 patients
18. Adjuvant chemotherapy after complete resection of non-small-cell lung cancer
19. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study)
20. Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: A randomized study
21. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials